SAN DIEGO, California and CALGARY, Canada, June 18 /PRNewswire/ --
- Findings Demonstrate Clear Trends of Proof of Principle of Reverse Cholesterol Transport in Human Volunteers
SAN DIEGO, California and CALGARY, Canada, June 18 /PRNewswire/ --
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announced today that it has completed the planned exploratory efficacy analysis of the data from the Phase I, 7 day RVX-208 treatment subjects. Analysis from two independent and external laboratories of blinded serum samples showed consistent improvements of key biomarkers for the RCT (reverse cholesterol transport) pathway.
"Analysis from 24 healthy volunteers in the 7 day RVX-208 trial showed statistically significant improvements over placebo in 3 of the 4 key variables assessed," stated Donald J. McCaffrey, President & CEO of Resverlogix. A fourth variable also showed positive trending but was not validated as statistically significant. McCaffrey emphasized, "All other lipid parameters behaved as anticipated. As efficacy is the one of the goals of our upcoming 28 day Phase 1b/2a trial we are very pleased to see the primary indicators behaving as they did. We were especially pleased to see the increases in pre-beta HDL of in excess of 30%, cholesterol efflux above 10%, serum ApoA-I above 10%, and HDL-C above 10% (not statistically significant) versus placebo. This follows a very similar improvement pattern as previously demonstrated by Resverlogix in the African Green Monkey studies. Crucial to these findings is the rapid onset of action in this 7 day trial, with the serum ApoA-I increases surpassing the previous 8% five week (35 day) average benchmark totals displayed by Pfizer's previous ApoA-I Milano recombinant protein studies."
McCaffrey continued, "What has been truly unique about RVX-208 versus other small molecule HDL/ApoA-I programs is that RVX-208 facilitates endogenous ApoA-I production. Resverlogix now has a commanding lead in the development of atherosclerosis therapeutics. To our knowledge no other small molecules, whether it is the statins, other HDL drugs or lipid modifying programs have demonstrated HDL functionality and RCT."
RCT is a pathway by which accumulated cholesterol is transported from the arterial wall to the liver for excretion, thus preventing atherosclerosis. Major constituents of RCT include acceptors such as high-density lipoprotein (HDL) and apolipoprotein A-I (ApoA-I). A critical part of RCT is cholesterol efflux, in which accumulated cholesterol is removed from macrophages.
Resverlogix will be presenting at the BIO Business Forum held in San Diego, California on Thursday June 19, 2008 at 1:15pm PDT in Room 4.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com.
This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.
For further information: Theresa Kennedy, VP, Corporate Communications, Resverlogix Corp., Phone: +1-604-538-7072, Fax: +1-403-256-8495, Email: Theresa@resverlogix.com; Sarah Zapotichny, Manager, Investor Relations, Resverlogix Corp., Phone: +1-403-254-9252, Fax: +1-403-256-8495, Email: Sarah@resverlogix.com Website: http://www.resverlogix.com/
SAN DIEGO, California and CALGARY, Canada, June 18 /PRNewswire/ --
For further information: Theresa Kennedy, VP, Corporate Communications, Resverlogix Corp., Phone: +1-604-538-7072, Fax: +1-403-256-8495, Email: Theresa@resverlogix.com; Sarah Zapotichny, Manager, Investor Relations, Resverlogix Corp., Phone: +1-403-254-9252, Fax: +1-403-256-8495, Email: Sarah@resverlogix.com .
Comments